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ARTICLE
Regulation of RIPK1 activation by TAK1-mediated
phosphorylation dictates apoptosis and necroptosis
Jiefei Geng1, Yasushi Ito1, Linyu Shi2, Palak Amin 1, Jiachen Chu1, Amanda Tomie Ouchida1,
Adnan Kasim Mookhtiar1, Heng Zhao1, Daichao Xu1, Bing Shan2, Ayaz Najafov 1, Guangping Gao3,
Shizuo Akira4 & Junying Yuan1,2
Stimulation of TNFR1 by TNFα can promote three distinct alternative mechanisms of cell
death: necroptosis, RIPK1-independent and -dependent apoptosis. How cells decide which
way to die is unclear. Here, we report that TNFα-induced phosphorylation of RIPK1 in the
intermediate domain by TAK1 plays a key role in regulating this critical decision. Using
phospho-Ser321 as a marker, we show that the transient phosphorylation of RIPK1 inter-
mediate domain induced by TNFα leads to RIPK1-independent apoptosis when NF-κB acti-
vation is inhibited by cycloheximide. On the other hand, blocking Ser321 phosphorylation
promotes RIPK1 activation and its interaction with FADD to mediate RIPK1-dependent
apoptosis (RDA). Finally, sustained phosphorylation of RIPK1 intermediate domain at multiple
sites by TAK1 promotes its interaction with RIPK3 and necroptosis. Thus, absent, transient
and sustained levels of TAK1-mediated RIPK1 phosphorylation may represent distinct states
in TNF-RSC to dictate the activation of three alternative cell death mechanisms, RDA, RIPK1-
independent apoptosis and necroptosis.
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RIPK1, a member of the receptor-interacting protein (RIP)serine-threonine kinase family, has emerged as a keyupstream regulator that controls multiple downstream
signaling pathways of TNFR11, 2. Within minutes after cells sti-
mulated by TNFα, RIPK1 is recruited into the TNFR1 signaling
complex (TNF-RSC, also called complex I) together with signal-
ing molecules such as TRADD, TRAF2 and cIAP1/2 to decide if a
cell and ultimately, an organism, may live or die through apop-
tosis or necroptosis. Apoptosis may be mediated by binding of
RIPK1, independent of its kinase activity, with FADD, an adaptor
protein for caspase-8, which in turn promotes the activation of
caspase-8 and executes apoptosis by triggering mitochondrial
damage and the cleavage of downstream caspases such as
caspase-3. Under apoptotic deﬁcient conditions, RIPK1 may be
activated to promote necroptosis by interacting with RIPK3
which in turn promotes the phosphorylation of MLKL to mediate
the execution of necroptosis.
Ubiquitination of RIPK1 by cIAP1/2 in TNF-RSC is involved
in mediating the activation of NF-κB by recruiting TAB1/2 to
promote the activation of the TAK1 (transforming growth factor-
β-activated kinase 1, also called MAP3K7)3. Activated TAK1
mediates the phosphorylation of IKKβ to promote the formation
of the IKK complex consisting of IKKα/β/γ(NEMO)4. Although
the best characterized function of TAK1 and the IKK complex
including NEMO is to mediate the activation of NF-κB pathway,
recent studies have unveiled that deﬁciencies in TAK1, NEMO,
IKKα/β or the loss of cIAP1/2 can sensitize cells to RIPK1-
dependent apoptosis (RDA) independently of their roles in NF-
κB activation5, 6. On the other hand, in cells deﬁcient for A20, an
important ubiquitin-editing enzyme for RIPK1, or TAB2, which
regulates the activation of TAK1, RIPK1 may be activated to
interact with RIPK3 to mediate necroptosis7, 8. It is not clear,
however, how activated RIPK1 might be directed to mediate two
alternative modes of cell death, RDA or necroptosis, that both
occur in a RIPK1 kinase-dependent manner.
RIPK1 contains an N-terminal kinase domain, an intermediate
domain and a C-terminal death domain1. The kinase activity of
RIPK1 may be activated upon stimulation of TNFR1 by TNFα
under selective conditions, which leads to multiple deleterious
consequences including cell death and inﬂammation. Inhibition
of RIPK1 kinase activity using improved necrostatin-1 (R-7-Cl-
O-Nec-1, Nec-1s), a highly speciﬁc small molecule inhibitor of
RIPK1, and the use of RIPK1 kinase-dead mutant mice, have
shown efﬁcacy in a wide range of animal models of human dis-
eases9–11. Small molecule inhibitors of RIPK1 are under clinical
and preclinical development targeting human diseases. However,
the molecular mechanism that controls the activation of RIPK1
kinase activity remains unclear.
Here we show that the intermediate domain of RIPK1 is
phosphorylated transiently by TAK1 upon TNFα stimulation in
wild-type (WT) cells in vitro and in vivo. While Ser321 (S321)
phosphorylation of RIPK1 by TAK1 has no effect on the NF-κB
activation, the loss of S321 phosphorylation promotes the binding
of RIPK1 to FADD and RDA. On the other hand, the sustained
TAK1-mediated phosphorylation of RIPK1 in multiple sites of
the intermediate domain including S321 promotes its interaction
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Fig. 1 TNFα induces RIPK1 phosphorylation at S321. a Alignment of amino acid sequences in the relevant part of RIPK1 intermediate domain from indicated
mammalian species. S321, S332, S334 and S336 as marked by arrowheads are highly evolutionarily conserved. b S321 of RIPK1 is transiently
phosphorylated after TNFα treatment. MEF cells were treated with TNFα (10 ng/ml) and the samples were collected at indicted time-points. The cell
lysates were analyzed by western blot. c Anti-p-S321-RIPK1 antibody speciﬁcally recognizes RIPK1 S321 phosphorylation. L929 cells were treated with TNFα
(20 ng/ml) for 5 min. The cell lysates were subjected to immunoprecipitation by either RIPK1 antibody or IgG. Both lysates and IP samples were examined
by western blot using anti-p-S321-RIPK1 and RIPK1 total antibodies. d, e TNFα induces RIPK1 S321 phosphorylation in murine primary BMDM and microglia
cells. BMDM d and primary microglia e were pre-incubated with DMSO or TAK1 inhibitor, 5Z-7 (0.5 µM) for 30min and treated with TNFα (10 ng/ml).
Samples were collected at indicated time-points. *, nonspeciﬁc bands
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with RIPK3 to mediate necroptosis. Our results elucidate the
molecular mechanism of interaction between TAK1 and RIPK1,
two critical mediators in the TNFα signaling pathway, distinct
from their roles in the activation of the NF-κB pathway, and the
mechanism by which the levels of RIPK1 phosphorylation control
the cellular choices for alternative cell death mechanisms.
Results
Transient RIPK1 S321 phosphorylation upon TNFα stimula-
tion. S321 of RIPK1 was found to be phosphorylated in the
kidney, lung and spleen tissues of mice under normal conditions
in a global phosphoproteomic study and when expressed in
293T cells11, 12. S321 site is evolutionarily conserved in RIPK1
proteins from species including mouse, human, rat and cattle
(Fig. 1a). S321 is located in a conserved sequence RMFSLQHDCV
in murine RIPK1, or RMQSLQLDCV in human RIPK1. The +1
residue of this peptide is a ‘Leu’, which is also found in +1 residue
of S177 in IKKβ known to be phosphorylated by TAK113.
To conﬁrm and characterize the signiﬁcance of S321
phosphorylation, we developed a phospho-speciﬁc antibody
against p-S321 of mouse RIPK1 (anti-p-S321-RIPK1). We probed
western blots of cell lysates from mouse embryonic ﬁbroblast
(MEF) cells stimulated with TNFα for different periods of time.
After stimulation of TNFα, the RIPK1 band showed a speciﬁc up-
shift within 5 min TNFα stimulation and the shift reduced after
30–60 min treatment. This shifted band was recognized by anti-p-
S321-RIPK1 (Fig. 1b). The phosphorylation of IKKβ, known to be
mediated by TAK113, was also detected during the same time
frame. Induction of RIPK1 S321 phosphorylation was also found
in RGC-5 cells stimulated by TNFα (Supplementary Fig. 1a). To
conﬁrm that the band recognized by anti-p-S321-RIPK1 is
RIPK1, we immunoprecipitated RIPK1 from cells stimulated by
TNFα and probed the immunocomplexes with anti-p-S321-
RIPK1. As shown in Fig. 1c, anti-p-S321-RIPK1 speciﬁcally
recognized immunoprecipitated RIPK1 from TNFα-stimulated
cells but not from control cells. In addition to MEF and RGC-5
cells, we veriﬁed TNFα induced RIPK1 phosphorylation in
primary cells. As that observed in MEFs and RGC-5 cells, in bone
marrow-derived macrophages (BMDM) and mouse primary
microglia stimulated by TNFα, the phosphorylation of RIPK1
S321 occurred in a similar pattern as that of IKKβ (Fig. 1d, e).
Thus, S321 of RIPK1 is phosphorylated transiently after TNFα
stimulation.
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Fig. 2 TAK1 phosphorylates RIPK1 at S321. a TNFα-induced RIPK1 S321 phosphorylation is inhibited by TAK1 inhibitor. BV-2 cells were treated by TNFα (20
ng/ml) together with DMSO, Nec-1s (10 µM), TBK1 inhibitor, BX795 (1 µM) and 5Z-7 (0.5 µM). b TAK1 is required for RIPK1 S321 phosphorylation. WT
and TAK1F/F MEFs with or without Cre expression were treated with TNFα (10 ng/ml) and 5Z-7 (0.5 µM) for 15 min and examined by indicated antibodies.
c Hyperphosphorylation of RIPK1 S321 in TAB2 KO MEF. TAB2 WT and KO MEFs were treated with TNFα (10 ng/ml) and the samples were collected at
indicated time-points. d FLAG-RIPK1 WT and S321A were expressed and puriﬁed from 293T cells and incubated with recombinant TAK1-TAB1 or GST-IKKα
or their inhibitors, 5Z-7 or PS1145, respectively. The products were analyzed by western blot using indicated antibodies. e RIPK1 S321 phosphorylation in
TNF-RSC. MEF cells were treated with FLAG-TNFα (50 ng/ml) for 5 min and TNF-RSC was puriﬁed by anti-FLAG immunoprecipitation. TNF-RSC
immunocomplexes were analyzed by western blot using indicated antibodies. *, nonspeciﬁc bands
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TAK1 phosphorylates RIPK1 S321. On the basis of the temporal
proﬁle of RIPK1 S321 phosphorylation upon stimulation by
TNFα, we focused on characterizing the involvement of TAK1
and TBK1 as possible kinases responsible for phosphorylating
RIPK1 S321 in response to TNFα stimulation. We treated L929
and BV-2 cells with TNFα in the presence of TAK1 inhibitor (5Z-
7-Oxozeaenol, 5Z-7) or TBK1 inhibitor (BX795). The treatment
with either TAK1 or TBK1 inhibitors blocked TNFα-stimulated
S321 phosphorylation in L929 cells (Supplementary Fig. 1b), but
only TAK1 inhibitor blocked the phosphorylation of S321 in
TNFα-stimulated BV-2 cells (Fig. 2a). 5Z-7 also inhibited phos-
phorylation of RIPK1 S321 in RGC-5, MEF, primary BMDM and
microglia cells stimulated by TNFα (Supplementary Fig. 1a, c and
Fig. 1d, e). To determine whether TBK1 might mediate the
phosphorylation of RIPK1 S321, we used CRISPR-Cas9 tech-
nology to generate TBK1 knockout (KO) BV-2 and MEF cells and
then stimulated the cells with TNFα. We found that the phos-
phorylation of RIPK1 S321 was not blocked, but rather enhanced
by TBK1 deﬁciency in both MEF and BV-2 cells (Supplementary
Fig. 1c, d). Therefore, we conclude that TBK1 is not the kinase
responsible for TNFα-induced RIPK1 S321 phosphorylation.
To provide deﬁnitive evidence for the role of TAK1 in
mediating phosphorylation S321 of RIPK1, we obtained MEFs
from mice homozygous for TAK1ﬂox/ﬂox allele (TAK1F/F)14. To
generate TAK1-deﬁcient MEFs, we excised the ﬂoxed genomic
fragment by infecting TAK1F/F MEFs with virus expressing Cre
and selected single colonies lacking the expression of TAK1
(TAK1F/F Cre). In TAK1F/F Cre MEFs, RIPK1 S321 phosphor-
ylation in response to TNFα was substantially abolished (Fig. 2b).
In contrast, the expression of Cre in WT MEF cells did not affect
the expression level of TAK1 or RIPK1 S321 phosphorylation in
response to TNFα (Fig. 2b), suggesting the blocked RIPK1 S321
phosphorylation in TAK1F/F Cre MEFs was not a result of virus
infection or Cre expression per se. Consistently, the phosphor-
ylation levels of p38 MAPK, a downstream target of TAK115,
were also reduced in TAK1F/F Cre MEFs but no in WT Cre MEFs
(Fig. 2b).
TAK1 activation in response to TNFα is transient, which peaks
at 5–10 min and decreases by TAB2-dependent recruitment of
protein phosphatases16. Deﬁciency in TAB2 leads to sustained
TAK1 activation and sensitized cells to necroptosis8, 16. We
therefore characterized RIPK1 S321 phosphorylation in WT and
TAB2 KO MEFs. We found that compared to that of WT MEFs,
the phosphorylation of RIPK1 S321 was enhanced and sustained
longer at later time-points in TAB2 KO MEFs when the signals in
WT MEFs were already subsided (Fig. 2c). Consistent with the
prolonged activation of TAK1, TNFα stimulation in TAB2 KO
MEFs also led to sustained phosphorylation of p38 and IKKβ
than that in WT cells.
Next we examined the ability of TAK1 to directly phosphor-
ylate RIPK1 by in vitro kinase assay. To minimize the effect of
auto-phosphorylation, we isolated kinase-dead RIPK1 protein,
RIPK1 K45M, as a substrate and incubated it with recombinant
TAK1 in the presence of 32P-ATP. When RIPK1 K45M was
incubated alone, only minimal level of phosphorylation could be
detected. When incubated with recombinant TAK1, RIPK1 was
phosphorylated and the phosphorylation was blocked in the
presence of TAK1 inhibitor (Supplementary Fig. 1e). Kinase-dead
IKKβ, a well characterized substrate of TAK1 was used as a
positive control. Phosphorylation of kinase-dead RIPK1 protein
with additional S321A mutation by TAK1 in radioactive kinase
assay was reduced but not eliminated (Supplementary Fig. 1e),
suggesting the additional TAK1 phosphorylation sites on RIPK1.
To further conﬁrm that the TAK1-mediated phosphorylation
occurred on S321, we puriﬁed RIPK1 WT and S321A mutant
proteins and examined whether they could be phosphorylated by
TAK1 in in vitro kinase assay. After incubation with recombinant
TAK1, only RIPK1 WT, but not RIPK1 S321A mutant, could be
recognized by anti-p-S321-RIPK1 antibody and the phosphoryla-
tion was inhibited in the presence of 5Z-7 (Fig. 2d). Thus, TAK1
can directly phosphorylate RIPK1 S321 in vitro.
Recently it was reported that IKKα/β could phosphorylate
RIPK15. Inhibition of TAK1 by 5Z-7 also blocked the activation
of IKKβ occurring downstream of TAK1 in response to TNFα
stimulation as expected (Supplementary Fig. 2a). To test the
possible contribution of IKKα/β to RIPK1 S321 phosphorylation,
we examined the effect of IKKα/β inhibitor, BMS345541, on
RIPK1 S321 phosphorylation. The presence of BMS345541
suppressed IκBα phosphorylation, which is known to be mediated
by IKKα/β kinase (Supplementary Fig. 2b)17. On the other hand,
the levels of phospho-RIPK1 S321 and phospho-IKKβ were
sustained even longer in presence of BMS345541 and TNFα
(Supplementary Fig. 2b). In addition, we conﬁrmed that
recombinant IKKα could phosphorylate RIPK1 in in vitro kinase
assay with 32P-ATP (Supplementary Fig. 2c) but the phosphory-
lated RIPK1 could not be recognized by anti-p-S321-RIPK1
antibody (Fig. 2d). Taken together, these results suggest that IKK
complex is not involved in mediating the phosphorylation of
RIPK1 S321.
The time-course study showed that phosphorylation of RIPK1
S321 occurred within 5 min of TNFα treatment, similar to that of
TAK1-mediated IKKβ phosphorylation (Fig. 1b, d, e). Since
TAK1 is transiently recruited to TNF-RSC within 5 min after
TNFα treatment, we next tested if the phosphorylation of RIPK1
S321 occurred in TNF-RSC. MEF cells were treated with FLAG-
tagged TNFα and TNF-RSC was puriﬁed by anti-FLAG
immunoprecipitation. Consistent with the phosphorylation by
TAK1, we detected the S321 phosphorylation of both high
molecular weight ubiquitinated and un-ubiquitinated
RIPK1 species in TNF-RSC, which was inhibited by 5Z-7
(Fig. 2e). Taken together, we conclude that TAK1 mediates the
phosphorylation of RIPK1 S321 in TNF-RSC upon TNFα
stimulation.
S321 phosphorylation of RIPK1 requires cIAP1/2. cIAP1-
mediated K63 ubiquitination of RIPK1 is known to be critical for
the recruitment of TAK1 into the TNF-RSC upon TNFα stimu-
lation18. To examine the role of K63 ubiquitination on RIPK1 in
TNFα-stimulated S321 phosphorylation, we treated cells with
SM-164, a small molecule IAP antagonist that can promote the
degradation of cIAP1/219. TNFα-induced RIPK1 ubiquitination
in TNF-RSC was substantially reduced in the presence of SM-164
(Supplementary Fig. 3a). Accordingly, TNFα-induced RIPK1
S321 phosphorylation was abolished after SM-164 treatment
(Fig. 3a). Furthermore, S321 phosphorylation was not detected in
TNFα-stimulated cIAP1/2 double knockout (DKO) cells (Fig. 3b).
Thus, cIAP1/2 is required for phosphorylation of RIPK1 S321
induced by TNFα.
To further characterize the requirement for RIPK1 ubiquitina-
tion in TAK1-mediated phosphorylation of S321, we examined
the requirement of TRADD, which is involved in the recruitment
of cIAP1/2 and TRAF2 to TNFR1, and TRAF2, an adaptor
protein for the recruitment of cIAP1/220. As shown in Fig. 3b, the
phosphorylation of S321 stimulated by TNFα was not detectable
in TRADD KO, or TRAF2 KO MEF cells. Consistent with the
requirement of K63 ubiquitination in phosphorylation of S321,
treatment with TAK1 inhibitor in the presence of SM-164 did not
further sensitize cells to TNFα-induced cell death (Supplementary
Fig. 3b). Taken together, these results suggest that cIAP1-
mediated K63 ubiquitination of RIPK1 is important for
promoting phosphorylation of RIPK1 S321.
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Since A20 is a critical ubiquitin-editing enzyme that can move
K63 ubiquitin chain from RIPK1 in TNFα-stimulated cells to
down-regulate TNFα signaling21, we examined the role of A20 in
regulating S321 phosphorylation of RIPK1. We found that TNFα-
induced RIPK1 S321 phosphorylation in A20-deﬁcient cells was
signiﬁcantly higher and persisted longer than that in WT cells
(Fig. 3c). Given the fact that A20-deﬁcient cells are hypersensitive
to RIPK1 activation and necroptosis22, this result suggests that
the possibility of elevated phosphorylation on RIPK1 by TAK1
may regulate the activation of RIPK1.
Phosphorylation of RIPK1 S321 regulates RDA. Next, we
explored the biological signiﬁcance of RIPK1 S321 phosphoryla-
tion. To determine whether RIPK1 S321 phosphorylation occurs
in vivo, we stimulated mice with TNFα via intraperitoneal
injections and characterized the phosphorylation of RIPK1 by
western blot. We found that TNFα stimulation in vivo was able to
induce the phosphorylation of RIPK1 S321 in the liver, kidney,
intestine and spleen (Fig. 4a). To determine the signiﬁcance of
RIPK1 S321 phosphorylation in vivo, we compared the effects of
virally transduced RIPK1 WT, S321A (SA) and S321E (SE)
expression in the liver, delivered using adeno-associated virus
(AAV) vector, a small single-stranded DNA-containing non-
pathogenic human parvovirus that has been used as an efﬁcient
vehicle for gene transfer to different tissues including liver
without apparent vector-related toxicities23. Speciﬁcally, we
constructed AAV vectors expressing FLAG-tagged RIPK1 WT,
S321A and S321E under the control of a liver-speciﬁc promoter
TBG24. We followed the effect of RIPK1 expression in C57BL/6
mice intravenously injected with RIPK1 expression AAVs using
plasma levels of alanine aminotransferase (ALT), a well-
established biomarker for liver damage. C57BL/6 mice are
known to be tolerogenic to rAAV gene delivery to the liver23.
Only a basal level of ALT release was found in the plasma of mice
received control (GFP-expressing) AAV. Interestingly, while low
levels of ALT release were detected in the plasma of mice
transduced with RIPK1 WT, signiﬁcantly elevated levels of ALT
were found in the plasma of mice that received RIPK1 S321A, but
not S321E, AAV (Fig. 4b). Furthermore, the levels of TNFα were
also signiﬁcantly higher in the liver tissues of mice that received
RIPK1 S321A virus (Fig. 4c). Importantly, the increased release of
ALT and TNFα was inhibited in mice treated with Nec-1s
(Fig. 4b, c). The effect of RIPK1 S321A virus to induce liver
damage was directly veriﬁed using TUNEL staining (Fig. 4d). The
expression level of FLAG-RIPK1 S321A was comparable to those
of WT and S321E, suggesting their different physiological effect
was not due to variations in expression levels (Fig. 4e). The
cleavage of RIPK1 S321A was elevated than that of WT in vivo,
while the cleavage of RIPK1 S321E was reduced (Fig. 4e). Thus,
the expression of S321A was more effective than that of RIPK1
WT or S321E in inducing RIPK1-dependent liver damage and
inﬂammation in vivo.
To better understand the signiﬁcance of RIPK1 S321
phosphorylation in regulating cell death, we generated knock-in
MEFs carrying RIPK1 S321A or S321E mutations by CRISPR-
Cas9 technology. Phosphorylation of S321 after TNFα stimula-
tion was eliminated in S321A(A/A) MEFs (Supplementary
Fig. 4a). S321A(A/A) or S321E(E/E) MEFs showed no difference
in the phosphorylation of IKKα/β, or in the phosphorylation or
degradation of IκBα in response to TNFα stimulation (Supple-
mentary Fig. 4b), suggesting that S321 mutation has no effect on
TNFα-stimulated NF-κB activation. Recruitment of CYLD, HOIP
and Sharpin to TNF-RSC in response to TNFα was not affected in
RIPK1 S321A(A/A) MEFs (Supplementary Fig. 4c). TNFα-
induced RIPK1 recruitment and ubiquitination in TNF-RSC
was slightly increased in RIPK1 S321A(A/A) MEFs (Supplemen-
tary Fig. 4d). On the other hand, homozygous S321A(A/A) MEFs
showed increased sensitivity to cell death induced by TNFα,
TNFα/cycloheximide (CHX) or TNFα/CHX/zVAD.fmk (zVAD)
and Nec-1s protected S321A(A/A) MEFs to all three treatments
(Fig. 5a–c). For better quantiﬁcation of apoptosis, WT and S321A
(A/A) MEFs were stained with SYTOX Green after TNFα alone
or TNFα/CHX treatment. As shown in Fig. 5d and Supplemen-
tary Fig. 5a, S321A(A/A) MEFs were more sensitive than WT cells
to apoptosis induced by TNFα or TNFα/CHX and Nec-1s only
protected cell death in S321A(A/A) MEF cells. While TNFα/CHX
normally promotes RIPK1-independent apoptosis in WT
cells, cell death of RIPK1 S321A(A/A) MEFs induced by TNFα
alone or TNFα/CHX was inhibited by Nec-1s, suggesting that the
lack of S321 phosphorylation sensitizes cells to TNFα-induced
RDA.
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Fig. 3 Ubiquitination of RIPK1 is essential for its phosphorylation by TAK1. a SM-164 treatment blocks RIPK1 S321 phosphorylation in L929 cells. The cells
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To verify the induction of RDA, we investigated the activation
of caspases and RIPK1 in S321A(A/A) MEFs. We found that the
activity of caspase-8 in S321A(A/A) MEFs, but not WT or S321E
(E/E) MEFs, was stimulated by TNFα alone (Fig. 5e). Consistent
with the activation of RDA, the addition of Nec-1s inhibited the
activation of caspase-8. Following the evidence of enhanced
caspase-8 activity, we examined the cleavage of RIPK1 and
CYLD, two well-established substrates of caspase-8. Augmented
cleavage of RIPK1 and CYLD was detected in S321A(A/A)
compared to WT MEFs after TNFα/CHX treatment (Supple-
mentary Fig. 5b). While the cleavage of CYLD and RIPK1 in both
WT and S321A(A/A) MEFs was inhibited by pan-caspase
inhibitor zVAD, the addition of Nec-1s was only able to inhibit
the cleavage of CYLD and RIPK1 in S321A(A/A) MEFs, but not
in WT MEFs, which further supports the induction of RDA in
S321A(A/A) MEFs.
RIPK1 is known to be cleaved after D324 in human RIPK1 (its
equivalent in murine RIPK1 is D325) by caspase-8 during TNFα
mediated apoptosis25. Since S321 is only one amino acid beyond
the usual 4-amino acid motif required for caspase recognition, we
tested if the phosphorylation of S321 or its single point mutant
might affect the cleavage by caspase-8 in vitro. However, S321A
mutation had no effect on the cleavage by caspase-8 in vitro while
S321E only showed weak increase of cleavage in vitro (Supple-
mentary Fig. 5c). Thus, instead of determining the sensitivity of
RIPK1 as a substrate for caspase-8, the phosphorylation of S321 is
involved in the regulation of caspase-8 activation.
RIPK1 S321A mutation promotes its binding with FADD.
Phosphorylation of RIPK1 S166 has been established as a bio-
marker of RIPK1 activation11, 26, 27. To determine if the activa-
tion of RIPK1 might be affected by the phosphorylation of S321,
we compared the phosphorylation of RIPK1 S166 in WT and
S321A(A/A) MEFs stimulated by TNFα, TNFα/CHX or TNFα/
CHX/zVAD. Stimulation of TNFα/CHX/zVAD is known to
activate RIPK1 and necroptosis26. Consistently, the phosphor-
ylation of RIPK1 S166 in WT MEFs was only detected upon
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Fig. 4 AAV-mediated RIPK1 S321A mutant expression induces liver damage in vivo. a Phosphorylation of RIPK1 S321 in mice tissues after TNFα injection.
30 µg TNFα were delivered to mice (8-week-old male) through intraperitoneal injections. Tissues were collected at 30 and 60min after the injection. RIPK1
was immunoprecipitated from tissue lysates by RIPK1 total antibody. b, c Liver damage in mice induced by AAV-mediated RIPK1 S321A mutant expression.
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stimulation by TNFα/CHX/zVAD together, but not by TNFα/
CHX or TNFα alone (Fig. 6a). On the other hand, the phos-
phorylation of RIPK1 S166 in S321A(A/A) MEFs stimulated by
TNFα/CHX/zVAD was signiﬁcantly higher than that of WT, and
furthermore, it was also detectable when stimulated by TNFα/
CHX or TNFα alone (Fig. 6a). In addition, K63 ubiquitination of
RIPK1 in TNFα-stimulated S321A(A/A) MEFs also increased
(Fig. 6b). These results suggest that TNFα or TNFα/CHX treat-
ment can promote the activation of RIPK1 when S321 phos-
phorylation is blocked. Given the increased caspase activity and
RIPK1 S166 phosphorylation in S321A(A/A) MEFs, we con-
cluded that blocking the phosphorylation of RIPK1
S321 sensitized cells to RDA upon stimulation by TNFα or
TNFα/CHX, which was not sufﬁcient to induce the activation of
RIPK1 in WT cells.
Consistent with increased activation of RIPK1, S321A(A/A)
MEFs also showed an increased sensitivity to necroptosis induced
by TNFα/CHX/zVAD, which was inhibited by the addition of
Nec-1s (Fig. 5a, c). On the other hand, the phosphorylation of
MLKL and the interaction of RIPK1 and RIPK3 to form complex
IIb, the hallmarks of necroptosis, were only detected in S321A(A/
A) MEFs when stimulated by TNFα/CHX/zVAD, but not by
TNFα/CHX (Fig. 6c, d). Thus, S321A mutation alone is not
sufﬁcient to activate necroptosis without caspase inhibition.
Since the activation of caspase-8 is mediated by the interaction
of RIPK1 with FADD, we next characterized the interaction of
RIPK1 and FADD in WT and S321A(A/A) MEFs by co-
immunoprecipitation. We found that compared to that of WT
MEFs, the interaction of RIPK1 and FADD in S321A(A/A) MEFs
after treatment with TNFα/CHX was signiﬁcantly increased.
Furthermore, the treatment with Nec-1s inhibited the interaction
of FADD and RIPK1 in S321A(A/A) MEFs but not in WT MEFs
induced by TNFα/CHX (Fig. 6e). Taken together, we conclude
that TAK1-mediated S321 phosphorylation on RIPK1 negatively
regulates its activation and interaction with FADD. Thus,
blocking S321 phosphorylation of RIPK1 sensitizes cells to
TNFα-induced RDA by promoting the interaction of RIPK1 and
FADD in a manner regulated by the kinase activity of RIPK1.
RIPK1 hyperphosphorylation promotes necroptosis. Hyper-
activation of TAK1 in TAB2 KO MEF has been shown to sen-
sitize cells to necroptosis8; however, the mechanism is unclear.
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measured in the presence or absence of zVAD as described in Methods. Error bar, s.e.m. *, t-test P< 0.05; **P< 0.01, ***P< 0.001. Three independent
repeats were included in each data point
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Given the enhanced phosphorylation on RIPK1 S321 in TAB2
KO cells, we hypothesized that hyperphosphorylation of RIPK1
by TAK1 might promote necroptosis. To test this hypothesis, we
ﬁrst characterized complex IIa formation and RIPK1 cleavage in
S321E(E/E) MEFs induced by TNFα/CHX. When treated with
TNFα/CHX, caspase-8-dependent RIPK1 cleavage was sig-
niﬁcantly reduced in S321E(E/E) MEF cells compared to WT
(Fig. 7a). Furthermore, RIPK1 was co-immunoprecipitated with
FADD in WT cells but not in S321E(E/E) mutant after 4 h TNFα/
CHX treatment (Fig. 7a). Although the pro-apoptosis complex IIa
was suppressed, RIPK1 S321E(E/E) MEFs were not more sensi-
tive to TNFα/CHX/zVAD-induced necroptosis compared to
WT cells (Fig. 5a). Thus, increased phosphorylation of RIPK1
S321 alone might not be sufﬁcient to drive necroptosis.
RIPK1 can be phosphorylated in a number of Ser residues close
to S321, e.g., S332 and S334 when expressed in 293T cells11. Since
the phosphorylation of S332/334 was not affected by RIPK1
kinase-dead K45M mutation, they were unlikely to be sites of
auto-phosphorylation. With additional S332/334/336A mutation,
RIPK1 phosphorylation by recombinant TAK1 in in vitro kinase
assay was further attenuated compared to kinase-dead RIPK1
S321A mutant (Supplementary Fig. 1e). To investigate the kinase
mediating RIPK1 S332/334 phosphorylation, we generated an
antibody against phosphorylation on these sites. Using this
antibody, we found that the phosphorylation of S332/334 RIPK1
was also detectable in early time-points after TNFα stimulation
and the signal was inhibited by 5Z-7, suggesting that they might
also be phosphorylated by TAK1 (Fig. 7b). Furthermore, the
signal detected by this p-S332/334 RIPK1 antibody was
eliminated by S321/332/334/336A (AAAA) mutation (Fig. 7c).
To characterize the effect of additional TAK1 phosphorylation
sites on RIPK1, we mutated these three TAK1 sites together with
S321 to generate RIPK1 S321/332/334/336E (EEEE) quadruple
mutant as a model for sustained RIPK1 phosphorylation in the
intermediate domain. We found that the expression of RIPK1
EEEE mutant in RGC-5 RIPK1 KO cells was sufﬁcient to induce
spontaneous RIPK1 kinase activation as shown by the detection
of RIPK1 S166 phosphorylation and its interaction with RIPK3 in
the absence of TNFα stimulation (Fig. 7d). Increased phosphor-
ylation of MLKL was detected in RGC-5 cells expressing RIPK1
EEEE mutant (Fig. 7e). As a result, RIPK1 EEEE mutant induces
spontaneous cell death which could be protected by RIPK3
knockdown or treatment of RIPK3 inhibitor (Fig. 7f). The
expression level of RIPK1 EEEE mutant was comparable to that
of other RIPK1 variants (Fig. 7d, e and Supplementary Fig. 6b), so
the activation of RIPK1 and RIPK3 as well as consequent cells
death were not due to higher expression of RIPK1 EEEE mutant.
Taken together, these results suggest that sustained RIPK1
phosphorylation in the intermediate domain promotes its
interaction with RIPK3 to drive necroptosis (Fig. 8).
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Discussion
In this manuscript, we demonstrate a novel mechanism by which
phosphorylation of the intermediate domain of RIPK1 by TAK1
dictates alternative cell death mechanisms. We show that dysre-
gulation of RIPK1 phosphorylation by TAK1, including both
inhibition or hyperphosphorylation, promotes the activation of
RIPK1. On the other hand, TAK1-mediated phosphorylation in
the intermediate domain of RIPK1 dictates whether RIPK1
interacts with FADD to form the complex IIa to mediate apop-
tosis in RIPK1-dependent or -independent manner, or with
RIPK3 to form the necrosome (complex IIb) to drive necroptosis.
Speciﬁcally, the lack of RIPK1 S321 phosphorylation by TAK1
promotes its interaction with FADD to mediate RDA; whereas
excessive phosphorylation of RIPK1 by TAK1 in the intermediate
domain promotes its interaction with RIPK3 while suppressing its
binding with FADD to promote necroptosis. In WT cells, TNFα-
induced transient phosphorylation of RIPK1 by TAK1 in the
presence of CHX is sufﬁcient to block the activation of RIPK1 and
drives RIPK1-independent apoptosis. On the other hand, the
absence of S321 phosphorylation on RIPK1 in TNFα alone or
TNFα/CHX-stimulated S321A(A/A) cells promotes the activation
of RIPK1 and RIPK1-dependent caspase activation to mediate
RDA. Finally, the sustained phosphorylation of RIPK1 by TAK1
modeled by RIPK1 EEEE mutant suppresses RIPK1-FADD
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interaction but promotes the interaction of RIPK1 and RIPK3 to
promote the activation of necroptosis in the absence of TNFα
stimulation. Thus, absent, transient and sustained levels of TAK1-
mediated RIPK1 phosphorylation in TNF-RSC may represent
three distinct states to dictate the execution of three alternative
cell death mechanisms, RDA, RIPK1-independent cell death and
necroptosis, by regulating the interaction of RIPK1 with FADD in
kinase-dependent or -independent manner to mediate apoptosis,
or with RIPK3 to mediate necroptosis (Fig. 8).
In TNFα-stimulated cells, TAK1 is recruited to TNFR1 in a
RIPK1-dependent manner to promote the phosphorylation of IκB
kinase (IKK) and activation of NF-κB pathway, which has a
powerful pro-survival role by inducing the expression of target
genes that can block apoptosis, promote cell proliferation and
stimulate inﬂammatory responses6, 28, 29. Our study deﬁnes a
novel molecular contribution of TAK1 that controls the activity
of RIPK1 kinase in mediating apoptosis, which is consistent, but
distinct, from the role of TAK1 in promoting cell survival and
inﬂammation in mediating NF-κB pathway activation. Support-
ing this idea, S321A mutation has no effect on the activation of
NF-κB when cells are stimulated by TNFα, as blocking NF-κB
activation by the addition of CHX, Smac mimetic, or TAK1
inhibitor, 5Z-7, is still required to signiﬁcantly induce apoptosis
in S321A(A/A) MEFs.
Our results demonstrate that deﬁciencies in TAB2 or A20
promote the phosphorylation of RIPK1 S321. Elevated levels of
RIPK1 phosphorylation in the intermediate domain in TAB2 KO
MEFs drive the interaction of RIPK1 and RIPK3 to promote
necroptosis. On the other hand, A20, encoded by the gene
TNFAIP3, is an important ubiquitin-editing enzyme recruited to
TNF-RSC to terminate multiple downstream events including
NF-κB-mediated transcriptional response, RIPK1-mediated sig-
naling and ultimately, the disassembly of the TNFR1 signaling
complex21, 30. K63 ubiquitination of RIPK1 is abnormally ele-
vated in A20-deﬁcient cells31. Since K63 ubiquitination of TNF-
RSC is critical for mediating the activation of TAK14, the
defective removal of K63 ubiquitination from TNF-RSC in A20-
deﬁcient cells are predicted to lead to sustained TAK1 activation.
However, since increased activation of TAK1 in A20-deﬁcient
cells is expected to promote sustained activation of NF-κB, it has
been puzzling as to why A20 deﬁciency also sensitizes cells to
necroptosis7. Our study reveals a previously unexpected link
between A20-regulated ubiquitination of TNF-RSC and TAK1-
mediated RIPK1 phosphorylation, which provides mechanistic
insights as how A20 deﬁciency might promote the activation of
RIPK1/RIPK3 complex to mediate necroptosis independent of
NF-κB activation. Recent genome-wide association studies have
identiﬁed single-nucleotide polymorphisms at the TNFAIP3/A20
locus in humans that are linked to susceptibility/resistance to
inﬂammatory and autoimmune diseases32. Our study also sug-
gests the possible clinical application of phospho-S320 in human
RIPK1 (equivalent to S321 in murine RIPK1) as a biomarker for
RIPK1-dependent cell death and inﬂammation.
Methods
Reagents antibodies and cell lines. The following commercial antibodies and
reagents were used in this study: TAK1, Cell Signaling Technology (5206); RIPK1,
Cell Signaling Technology (3493) and BD Biosciences (610459); TBK1, Cell Sig-
naling Technology (3504); p-IKKα/β, Cell Signaling Technology (2697); IKKβ, Cell
Signaling Technology (8943); IκBα, Santa Cruz (sc-371); p-p38, Cell Signaling
Technology (9211); p38, Cell Signaling Technology (9212); CYLD, Cell Signaling
Technology (8462); FADD, Abcam (ab124812) and Santa Cruz (6036); α-Tubulin,
Sigma-Aldrich (T9026); β-actin, Santa Cruz (81178). α-Tubulin and β-actin anti-
bodies were used with 5000-fold dilution and other antibodies were used with
1000-fold dilution. Uncropped scans of the most important blots were provided as
Supplementary Fig. 7 in the Supplementary Information. 5Z-7 was from Sigma-
Aldrich (O9890). Recombinant TAK1-TAB1 and GST-IKKα fusion proteins were
obtained from Millipore (14-600) and Sigma (SRP5040). CellTiter-Glo luminescent
cell viability kit was from Promega. 7-Cl-O-Nec-1 (Nec-1s) was made by custom
synthesis. L929 and BV-2 cells were purchased from ATCC. TRAF2 and TRADD
KO MEFs were provided by Dr. Zhenggang Liu. cIAP1/2 DKO MEFs were pro-
vided by Dr. John Silke. TAB2 KO MEFs were provided by Dr. Jun Ninomiya-
Tsuji. Cell lines used in this study were tested every 3 months for mycoplasma
contamination by MycoAlert Mycoplasma Detection Kit from Lonza.
Generation of anti-p-RIPK1 S321 and S332/334 antibodies. The phospho-
peptides, VLQRMFpSLQHDC (S321) and CVPLPPpSRpSNSEQPG (S332/334),
were synthesized and coupled to KLH carrier protein via Cys at the C terminus.
Polyclonal anti-p-S321 or p-S332/334 RIPK1 antibodies were produced in rabbits
against p-peptide antigen by ProteinTech.
AAV-RIPK1 vector and virus production. rAAV vector plasmids carrying the
vector genomes with WT, S321A or S321E RIPK1 gene expression cassettes under
the control of human thyroxine binding globulin (TBG) promoter, which directs
efﬁcient and sustaining transgene expression in liver-speciﬁc pattern24, are trans-
fected individually into HEK293 cells with a packaging plasmid and adenovirus
helper plasmid. The recombinant viruses were puriﬁed by standard CsCl gradient
sedimentation method and desalted by dialysis33. The quality of vectors was tested
by qPCR titration for DNase resistant vector genome concentration, silver-stained
SDS-polyacrylamide gel analysis to establish the purity of each lot, electron
microscopic analysis to independently test full/empty virus ratios33.
Generation of TAK1F/F and RIPK1 mutant MEFs. Super-ovulated female B6D2F1
mice (7–8 weeks old) were mated to B6D2F1 vasectomy males, and zygotes were
collected from oviducts. Cas9 mRNA and sgRNA were prepared by in vitro
transcription. Single-stranded oligonucleotides (ssODN) were synthesized by
Sangon. 100 ng/μl Cas9 mRNA, 50 ng/μl sgRNA and 100 ng/μl ssODN were mixed
in M2 medium (Sigma) and injected into the cytoplasm of zygote using a micro-
injector (FemtoJet, Eppendorf). The injected zygotes were cultured in KSOM with
amino acids at 37 °C under 5% CO2 in air until transplantation. Thereafter, 20–25
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P P
TAK1 KO, 5Z-7, SM-164 TAB2 KO, A20 KO
RIPK1-FADD interaction
caspase activation
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KD: kinase domain
ID: intermediate domain
DD: death domain
No phosphorylation Transient phosphorylation Sustained phosphorylation
RIPK1 kinase activationRIPK1 kinase activation
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RIPK1-independent
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RIPK1-dependent
apoptosis
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Fig. 8 TAK1-mediated RIPK1 phosphorylation dictates the activation
multiple cell death pathways. Upon TNFα treatment, TAK1 is activated to
mediate RIPK1 phosphorylation on the intermediate domain. Under normal
conditions, TNFα/CHX induces transient phosphorylation of RIPK1 S321 by
TAK1 and leads to RIPK1-independent apoptosis. Dysregulation of RIPK1
phosphorylation by TAK1 promotes its activation. When the
phosphorylation of RIPK1 intermediate domain is blocked as in TAK1 KO
cells, with inhibitor of TAK1 or IAP antagonist (SM-164), TNFα alone or
TNFα/CHX treatment promotes the activation of RIPK1 and its binding with
FADD to mediate RDA. On the other hand, hyperphosphorylation of RIPK1
intermediate domain, as in TNFα-stimulated TAB2 KO and A20 KO cells,
promotes its interaction with RIPK3 to mediate necroptosis
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injected embryos were transferred into oviducts of pseudopregnant ICR females at
0.5 d.p.c. The pups were identiﬁed by both enzyme digestion and DNA sequencing.
The positive mice were mated with WT C57BL/6 mice to produce heterozygous
S321A or E mutant progenies, which are then backcrossed with C57BL/6 mice.
Target sequence:
5′-TTTGACCTGCTCGGAGGTAA-3′
S321A ssODN (the synonymous mutation were highlighted by bold and point
mutations were highlighted by Italic):
5′-cattacagaaagagtatccagatcaaagcccagtgctgcagagaatgtttGCATTGCAGCATGAC
TGTGTACCCTTGCCGccgagcaggtcaaattcaggtaactcacctattcgttcatttgcatactc-3′
S321E ssODN:
5′-cattacagaaagagtatccagatcaaagcccagtgctgcagagaatgttt
GAATTGCAGCATGACTGT
GTACCCTTGCCGccgagcaggtcaaattcaggtaactcacctattcgttcatttgcatactc-3′
The founder mice carrying S321A or S321E mutant were backcrossed with
C57BL/6 mice to produce heterozygous mice. WT and homozygous S321A(A/A)
or WT and homozygous S321E(E/E) embryonic ﬁbroblast cells were isolated from
littermates of E13.5 embryos of heterozygous crosses. All experiments on mice
were conducted according to the protocols approved by the Harvard Medical
School Animal Care Committee and Institutional Animal Care and Use Committee
of the Interdisciplinary Research Center on Biology and Chemistry of Chinese
Academy of Sciences.
TAK1F/F MEFs were immortalized spontaneously in culture and infected by
virus for the expression of Cre recombinase to generate TAK1-deﬁcient MEF.
RIPK1 S321A and S321E MEFs were immortalized by viral infection and
subsequent expression of SV-40 large T antigen.
Caspase activity assay. Cell lysates were collected and mixed with substrate for
caspase-8 (caspase-Glo 8 Assay, Promega) and the activity was determined
according to the manufacturer’s instructions.
In vitro caspase-8 cleavage assay. RIPK1 WT, S321A and S321E plasmids were
transcribed and translated in vitro with [35S]-methionine labeling using TNT T7
Quick coupled transcription/translation kit (Promega). In vitro cleavage assay was
performed in cleavage buffer containing 20 mM HEPES (pH= 7.4), 100 mM NaCl,
20 mM dithiothreitol and 0.5% NP-40 at 37 °C for 1 h34.
In vitro kinase assay. Kinase-dead FLAG-RIPK1 variants with or without addi-
tional mutations or kinase-dead IKKβ were transiently expressed in 293T and
immunoprecipitated with anti-FLAG M2-agarose beads. Protein bound FLAG
beads were incubated with 100 ng recombinant TAK1 in kinase buffer containing
20 mM HEPES (pH= 7.3), 10 mM MgCl2, 10 mM MnCl2, 10 µM cold ATP and 1
µCi of [γ-32P]ATP11. When indicated in the text, 1 µM 5Z-7 was added to the
reaction mixture. The reactions were carried out at 30 °C for 60 min and stopped
by boiling in SDS-PAGE loading buffer at 95 °C for 5 min. Similar protocol was
used for RIPK1 S321A phosphorylation assay. To conﬁrm anti-p-S321-RIPK1
antibody speciﬁcity, 293T cells transiently expressing FLAG-RIPK1 WT or S321A
were treated with 5Z-7 (0.5 µM) and Nec-1s (10 µM) to minimize RIPK1 phos-
phorylation background. RIPK1 WT and S321A mutant were puriﬁed and incubate
with recombinant TAK1 or IKKα in kinase buffer without [γ-32P]ATP at 30 °C for
30 min.
Statistics. Data are expressed as the mean± s.e.m. Error bar, s.e.m. Pairwise
comparisons between two groups were performed using the Student’s t-test.
Differences were considered statistically signiﬁcant if P< 0.05 (*), P< 0.01 (**),
P< 0.001 (***) or not signiﬁcant (n.s.). At least three independent biological
repeats were included in each data point. Each experiment was repeated at least
three times.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information Files.
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